Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intra-arterial Tenecteplase · 1 trial · 1 indication
Number of participants with symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage) producing decline from the initial National Institutes of Health Stroke Scale (NIHSS) of ≥ 4 points.
Number of participants with parenchymal hematoma type 1
Number of participants with parenchymal hematoma type 2
Number of patients expired
Number of patients expired
Total number of grade 3 adverse events
| Arm | Type | Description |
|---|---|---|
| Intra-arterial Tenecteplase | EXPERIMENTAL | Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of intra-arterial Tenecteplase (0.125 mg/kg, maximum dose 12.5 mg) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
| Intra-arterial Saline | PLACEBO_COMPARATOR | Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of saline (0.9% NaCl solution) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
| Name | Type | Description |
|---|---|---|
| Intra-arterial Tenecteplase | DRUG | One-time dose of intra-arterial tenecteplase post-thrombectomy |
| Intra-arterial Saline | DRUG | One-time dose of intra-arterial saline post-thrombectomy |
Inclusion Criteria: * Patient/legally authorized representative has signed the Informed Consent Form * Ability to comply with the study protocol, in the investigator's judgment * Functionally independent (modified Rankin scale 0-2) prior to presentation * Baseline National Institutes of Health Stro...
Intra-arterial tenecteplase is being studied for acute ischemic stroke, specifically in patients with large vessel occlusion who have undergone endovascular thrombectomy. It is delivered directly into the artery as an adjunct treatment following the clot removal procedure. The drug remains investigational and is not approved for commercial use.
Roche Holding AG is developing intra-arterial tenecteplase. The company trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating this therapy in acute ischemic stroke.
Intra-arterial tenecteplase is in Phase 2 clinical development. The single ongoing trial is a Phase 2 study, and no Phase 3 trials have been initiated. The drug is investigational and has not received FDA approval.
Intra-arterial tenecteplase is being evaluated in one clinical trial: NCT06781385, titled "Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke." The trial is currently enrolling by invitation, with a planned enrollment of 40 participants, and is being conducted in the United States.
The Phase 2 trial NCT06781385 is a randomized, double-blind, placebo-controlled study. It plans to enroll 40 adults aged 18 years and older of all sexes. Participants must have acute ischemic stroke with large vessel occlusion and have undergone endovascular thrombectomy. Healthy volunteers are not eligible.